These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36807681)

  • 21. Effect of ethanol concentrations on temperature driven structural changes of chymotrypsin inhibitor 2.
    Mohanta D; Jana M
    J Chem Phys; 2016 Apr; 144(16):165101. PubMed ID: 27131567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A structural model of polyglutamine determined from a host-guest method combining experiments and landscape theory.
    Finke JM; Cheung MS; Onuchic JN
    Biophys J; 2004 Sep; 87(3):1900-18. PubMed ID: 15345567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Titration properties and thermodynamics of the transition state for folding: comparison of two-state and multi-state folding pathways.
    Tan YJ; Oliveberg M; Fersht AR
    J Mol Biol; 1996 Nov; 264(2):377-89. PubMed ID: 8951383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The structure of the transition state for the association of two fragments of the barley chymotrypsin inhibitor 2 to generate native-like protein: implications for mechanisms of protein folding.
    de Prat Gay G; Ruiz-Sanz J; Davis B; Fersht AR
    Proc Natl Acad Sci U S A; 1994 Nov; 91(23):10943-6. PubMed ID: 7971988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Context dependence of protein secondary structure formation: the three-dimensional structure and stability of a hybrid between chymotrypsin inhibitor 2 and helix E from subtilisin Carlsberg.
    Osmark P; Sørensen P; Poulsen FM
    Biochemistry; 1993 Oct; 32(41):11007-14. PubMed ID: 8218165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant chymotrypsin inhibitor 2: expression, kinetic analysis of inhibition with alpha-chymotrypsin and wild-type and mutant subtilisin BPN', and protein engineering to investigate inhibitory specificity and mechanism.
    Longstaff C; Campbell AF; Fersht AR
    Biochemistry; 1990 Aug; 29(31):7339-47. PubMed ID: 2207109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational Design of Chymotrypsin Inhibitor 2 by Optimizing Non-Native Interactions.
    B da Silva F; M de Oliveira V; Sanches MN; Contessoto VG; Leite VBP
    J Chem Inf Model; 2020 Feb; 60(2):982-988. PubMed ID: 31794216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Following co-operative formation of secondary and tertiary structure in a single protein module.
    Neira JL; Itzhaki LS; Ladurner AG; Davis B; de Prat Gay G; Fersht AR
    J Mol Biol; 1997 Apr; 268(1):185-97. PubMed ID: 9149151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of protein-protein interactions by mutagenesis: direct versus indirect effects.
    Otzen DE; Fersht AR
    Protein Eng; 1999 Jan; 12(1):41-5. PubMed ID: 10065709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme dynamics from NMR spectroscopy.
    Palmer AG
    Acc Chem Res; 2015 Feb; 48(2):457-65. PubMed ID: 25574774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure of the transition state for folding of a protein derived from experiment and simulation.
    Daggett V; Li A; Itzhaki LS; Otzen DE; Fersht AR
    J Mol Biol; 1996 Mar; 257(2):430-40. PubMed ID: 8609634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Model process for separation based on unfolding and refolding of chymotrypsin inhibitor 2 in thermoseparating polymer two-phase systems.
    Umakoshi H; Persson J; Kroon M; Johansson HO; Otzen DE; Kuboi R; Tjerneld F
    J Chromatogr B Biomed Sci Appl; 2000 Jun; 743(1-2):13-9. PubMed ID: 10942268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coordination topology and stability for the native and binding conformers of chymotrypsin inhibitor 2.
    Baysal C; Atilgan AR
    Proteins; 2001 Oct; 45(1):62-70. PubMed ID: 11536361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probing the free energy landscape of the fast-folding gpW protein by relaxation dispersion NMR.
    Sanchez-Medina C; Sekhar A; Vallurupalli P; Cerminara M; Muñoz V; Kay LE
    J Am Chem Soc; 2014 May; 136(20):7444-51. PubMed ID: 24805164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and characterization of the unfolding transition state of chymotrypsin inhibitor 2 by molecular dynamics simulations.
    Li A; Daggett V
    J Mol Biol; 1996 Mar; 257(2):412-29. PubMed ID: 8609633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conserved residues and the mechanism of protein folding.
    Shakhnovich E; Abkevich V; Ptitsyn O
    Nature; 1996 Jan; 379(6560):96-8. PubMed ID: 8538750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural interpretation of hydrogen exchange protection factors in proteins: characterization of the native state fluctuations of CI2.
    Best RB; Vendruscolo M
    Structure; 2006 Jan; 14(1):97-106. PubMed ID: 16407069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ratcheted molecular-dynamics simulations identify efficiently the transition state of protein folding.
    Tiana G; Camilloni C
    J Chem Phys; 2012 Dec; 137(23):235101. PubMed ID: 23267502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational analysis of the N-capping box of the alpha-helix of chymotrypsin inhibitor 2.
    elMasry NF; Fersht AR
    Protein Eng; 1994 Jun; 7(6):777-82. PubMed ID: 7937708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Folding of chymotrypsin inhibitor 2. 2. Influence of proline isomerization on the folding kinetics and thermodynamic characterization of the transition state of folding.
    Jackson SE; Fersht AR
    Biochemistry; 1991 Oct; 30(43):10436-43. PubMed ID: 1931968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.